A rare deafness-dystonia syndrome is discovered by a research team from Pakistan, Europe and Singapore.
The research, published in Disease Models & Mechanisms
was found to describe five out of the eight children in a family who had developed a range of symptoms when they grew, hearing impairment which developed at six months of age that can further develop into profound deafness by ten years. This was also found to be accompanied by delayed motor development.
‘Newly discovered deafness-dystonia syndrome highlights the importance of rare disease research.’
This condition has been named 'Siddiqi syndrome' for Dr Saima Siddiqi from the Institute of Biomedical and Genetic Engineering in Islamabad, Pakistan, who initially made contact with the family. A research team, led by Dr Siddiqi and Dr Hannie Kremer from the Radboud University Medical Center in Nijmegan, The Netherlands, used whole-exome sequencing to identify a single homozygous nonsense mutation in the gene for FITM2, a protein involved in lipid droplet formation and energy metabolism. To confirm their discovery, the team reduced the activity of the homologous gene in fruit flies and found that these flies displayed hearing and locomotor impairments, as seen in the affected family. The researchers were further able to clarify that reduced activity of the gene causes abnormal branching of sensory neurons in flies as they develop.
Making the connection
Directing resources to rare disease research might not always be the obvious choice when the results will apparently benefit only a small group of people. However, Dr Siddiqi explains that rare diseases in remote and underdeveloped regions like Pakistan are not necessarily as rare as might be thought since a lack of facilities and funding prevents proper disease management and diagnosis.
It might also only take one published study on a rare disease to start making connections to other patients for whom a diagnosis is still elusive. Dr Kremer says, "Upon publication of the paper, I was contacted by a clinical geneticist about a patient in his clinic with two mutated copies of the FITM2 gene. So there might be a second family now and further clinical examinations are being performed in the young patient to determine to which extent the disease is similar to the disease in the published family." She adds that research into rare diseases can also yield surprising results. For example, the patients with the FITM2 mutation did not have any signs of lipodystrophy, contrary to expectations based on what is currently known about the function of the gene in lipid droplet formation. Dr Siddiqi further explains that this new knowledge about the function of FITM2 might have future implications for improving diagnosis and treatment for other diseases involving defects in FITM2 and lipid droplet formation, such as non-alcoholic fatty liver disease and type 2 diabetes. This shines a clear spotlight on how rare disease research can provide important breakthroughs for more common diseases.
A ray of hope
To patients with rare diseases and their families, studies like this offer a ray of hope. Dr Kremer describes how obtaining a diagnosis is of tremendous importance as parents can spend many years consulting with medical professionals trying to find out what is wrong with their child. Finally understanding the nature of the disease can help to relieve feelings of guilt parents often experience that something they did might have caused the condition. Dr Kremer also explains how "a diagnosis provides the opportunity for parents and/or patients to be in contact with other families in which the same disease occurs and they can learn from each other about problems and solutions." Dr Siddiqi adds, "Now this family in Pakistan knows that they have genetic disease running in their family and that they need carrier screening for couples. Although this diagnosis has deprived them of the hope that they can be treated immediately, to me it's the start of new hope for them... that one day they will have a definite treatment."